- Home
- PED vs CTSO Comparison
PED vs CTSO Comparison
Compare PED & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PED | CTSO |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.3M | 45.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PED | CTSO |
|---|---|---|
| Price | $0.58 | $0.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $1.50 | ★ $5.38 |
| AVG Volume (30 Days) | ★ 149.0K | 140.1K |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.43 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | $33,244,999.00 | ★ $36,979,520.00 |
| Revenue This Year | N/A | $7.26 |
| Revenue Next Year | $305.89 | $9.78 |
| P/E Ratio | $5.53 | ★ N/A |
| Revenue Growth | N/A | ★ 23.89 |
| 52 Week Low | $0.43 | $0.60 |
| 52 Week High | $1.00 | $1.61 |
Technical Indicators
Market Signals| Indicator | PED | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 54.67 | 47.12 |
| Support Level | $0.54 | $0.62 |
| Resistance Level | $0.60 | $0.68 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 72.18 | 37.05 |
Price Performance
Historical ComparisonAbout PED Pedevco Corp.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.